three tidbit note
highlight three quick point speak ir
post call updat model tweak estim
rais ep maintain ew
clarifi manag ex-u humira forecast rough forecast
repres declin yoy includ expect
oper declin plu neg fx hit usd strengthen vs eur
regard full year manag maintain project
oper declin note ex-u humira easi comp full
year forecast remain unchang quarterli progress
learn risankizumab skyrizi royalti hit gross margin
incom statement henc assum risankizumab above-
averag gross margin product royalti partner boehring ingelheim
privat account conting consider reflect
oper cash flow manag provid color yet royalti
orilissa ramp strongli cours manag maintain
sale estim expect greater adopt market
becom awar new endometriosi pain treatment lower
full year estim includ
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
pt base base case ep price-to-earnings multipl
peer mean due risk long-term humira declin
bull case ep
bull case ep
sale surpass expect drive ep project pipelin
develop deliv upsid surpris settl humira litig bi
us biosimilar entri later add new long-term growth driver
diversifi beyond humira help price-to-earnings
base case ep
base case ep
see balanc risk-reward expect strong ep growth posit
pipelin develop near-term balanc long-term humira biosimilar
threat includ risk us biosimilar interchang bi candid
bear case ep
bear case ep
earn forecast newsflow concern major franchis sale
disappoint caus ep expect pipelin candid
upadacitinib approv delay bi make progress overcom humira
patent investor discount us biosimilar entri rather
equal-weight share
anticip solid ep growth
posit pipelin develop
growth near-medium term
balanc risk price-to-earnings contract long term
us biosimilar humira entri approach
like pursu extern
transact enhanc pipelin
surpris neg humira sale patent
financi result rel expect
humira imbruvica hcv sale
litig interchang trial readout
clinic trial result potenti btk
competitor imbruvica includ
acalabrutinib trial cll
extern busi develop
risk achiev price
upsid risk result
posit humira patent news value-
downsid risk result
disappoint problemat legal
price
price
price
exhibit trade mean histor mean
price data
price data
exhibit incom statement margin analysi valuat
sg sale
 sale
exhibit balanc sheet statement
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
